Matthew Fowler

Treatment with this combination was associated with encouraging clinical responses in this patient population.

Immunotherapy could help a segment of patients with metastatic prostate cancer, a study found.

“The improvement in disease-free survival following surgery that was seen in the ADAURA study supports the use of this targeted therapy in an earlier stage of disease,” said ASCO chief medical officer and executive vice president Dr. Richard L. Schilsky.